News

GSK plc (GSK) Stock Rises as FDA Approves Nucala for COPD, CHMP Backs Blenrep for Cancer Treatment
GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...
pharmaphorum1d
GSK claims first approval for Nucala in COPD
While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...
STAT1d
GSK drug’s new approval sets up competition with Dupixent
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.
The American Journal of Managed Care1d
FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype
FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
Pharmaceutical Technology4d
ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history
At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...
Endpoints News1d
GSK’s Nu­cala wins COPD ap­proval, stok­ing ri­val­ry with Dupix­ent
GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...